Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature...
Pierre Fabre Laboratories announced today that the European Medicines Agency (EMA) validated the submission for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Novel combinations are in development for the treatment of patients with BRAF V600-muated non–small cell lung cancer (NSCLC), and although resistance remains a challenge and questions regarding how to best sequence targeted agents in the treatment paradigm, encorafenib (Braftovi) plus binimetinib (Mektovi) has shown promising efficacy in this patient population, according to Corey J. Langer, MD.
Sandoz's Generic Encorafenib Receives Approval in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for BRAFTOVI® (encorafenib) in combination with cetuximab which is currently FDA-approved for adult patients with previously treated metastatic colorectal cancer (mCRC) harboring a BRAF V600E alteration. This now makes FoundationOne Liquid CDx the only comprehensive genomic profiling (CGP) test FDA-approved to identify patients with BRAF V600E alterations in mCRC who may be appropriate for treatment with BRAFTOVI in combination with cetuximab.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed...
Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups.
Amber Specialty Pharmacy announces today that they will begin dispensing 13 Pfizer oncology products. The pharmacy’s comprehensive service model will support patients, caregivers, and oncology specialists throughout the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.
FDA Confirms Para IV Patent Litigation for Encorafenib capsules.